How Immune Cells Called Dendritic Cells Drive Type 1 Diabetes

Dendritic cells are immune cells that act as messengers between the body's innate defenses and its adaptive immune system. They sense danger signals in the body, capture antigens (foreign or self-proteins), and present them to T cells—immune cells that decide whether to attack or tolerate what they see.

Because of this middle-ground role, dendritic cells are uniquely positioned to either promote immune tolerance or trigger immune attack. In a healthy immune system, they help maintain tolerance to the body's own tissues. But when something goes wrong, they can shift toward activating autoreactive T cells—cells that mistakenly attack the body's own cells.

In Type 1 diabetes, dendritic cells contribute to disease in several ways. They present beta cell antigens—proteins from the insulin-producing cells—to T cells in a way that activates rather than tolerates them. This breakdown of tolerance is a hallmark of Type 1 diabetes.

Beyond presenting antigens, dendritic cells amplify insulitis, the chronic inflammation of the pancreatic islets where insulin is made. They do this by producing inflammatory cytokines (signaling molecules) and recruiting other immune cells to the site of beta cell damage.

Dendritic cells can shift their function through a process called metabolic reprogramming. This means they change how they use energy and nutrients, which in turn affects what signals they send to other immune cells. They may also become more prone to activating inflammasomes—molecular structures that trigger inflammation—and to producing cytokines that promote autoimmunity rather than tolerance.

Understanding these metabolic and signaling changes is important because it reveals potential intervention points. If researchers can redirect how dendritic cells process antigens and produce signals, they might be able to restore immune tolerance rather than activate immune attack.

Researchers are now exploring ways to reprogram dendritic cells as a therapeutic strategy. The goal is to shift dendritic cells from promoting autoimmunity toward promoting tolerance—essentially teaching them to present beta cell antigens in a way that quiets the immune response rather than activating it.

While this research identifies promising mechanistic targets, the translation from laboratory findings to clinical treatments remains in early stages. Much work is needed to determine whether these approaches can be safely and effectively applied to prevent or slow Type 1 diabetes in people.

Source: International journal of molecular sciences. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.